CVS Caremark®

|  |
| --- |
| Reference number(s) |
| 3029-A |

# Specialty Guideline Management Duopa

## Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

| Brand Name | Generic Name |
| --- | --- |
| Duopa | carbidopa/levodopa enteral suspension |

## Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

### FDA-approved Indications

Duopa is indicated for the treatment of motor fluctuations in patients with advanced Parkinson’s disease.

All other indications are considered experimental/investigational and not medically necessary.

## Coverage Criteria

### Parkinson’s Disease

Authorization of 6 months may be granted for treatment of motor fluctuations in members with advanced Parkinson’s disease when all of the following criteria are met:

* Member is levodopa responsive with clearly defined “on” periods.
* The member has “off” periods of at least 3 hours per day despite optimization efforts.
* The member must have had an inadequate response or intolerable adverse event with oral carbidopa/levodopa and one of the following anti-Parkinson agents:
  + Dopamine agonist (e.g., pramipexole, ropinirole)
  + Monoamine oxidase-B (MAO-B) inhibitor (e.g., selegiline, rasagiline)
  + Catechol-O‐methyltransferase (COMT) inhibitor (e.g., entacapone, tolcapone)

## Continuation of Therapy

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for advanced Parkinson’s disease who have demonstrated a positive clinical response with the requested medication.

## References

1. Duopa [package insert]. North Chicago, IL: AbbVie, Inc; March 2022.
2. Olanow CW, Keiburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomized, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141-149. doi:10.1016/S1474-4422(13)70293-X